Section III · Markets

Biotech Catalyst Daily · Archive

Every past edition. New briefings publish every weekday by 7:00 AM Eastern.

May 22, 2026 Biogen's Parkinson's Therapy Fails; Merck's Lung Drug Success Biogen and Denali drop Parkinson's drug; Merck's ADC shows promise in lung cancer.
May 21, 2026 Lilly's obesity drug shows bariatric-level weight loss Eli Lilly's latest trial results could reshape obesity treatments.
May 20, 2026 Guardant's FDA Approval Boosts Liquid Biopsy Market Guardant360's FDA nod positions Guardant for growth in cancer diagnostics.
May 19, 2026 Relay's promising data boosts R&D prospects amid mergers Relay's Phase 2 results and InMed's merger signal shifts in biotech strategies.
May 18, 2026 Regeneron faces setbacks as AstraZeneca gains FDA approval Regeneron’s melanoma trial flops while AstraZeneca secures key FDA approval for hypertension drug.
May 15, 2026 Mid-size biopharma firms ramp up M&A activity 2026 is shaping up to be a record year for biopharma M&A as mid-size firms lead the charge.
May 14, 2026 Regenxbio's Duchenne therapy aims for 2027 FDA approval New trial data impacts Regenxbio; Biogen's Alzheimer's drug misses goals.
May 13, 2026 Tessera's Sickle Cell Data Challenges Gene Therapy Norms Tessera's new therapy could disrupt the sickle cell treatment landscape.
May 12, 2026 Bristol Myers' $15.2B deal with Hengrui Pharma signals growth Bristol Myers teams with Hengrui on a major licensing deal for 13 drugs.
May 11, 2026 CSL's stock hits nine-year low after $5B write-down Braveheart Bio's cardiac drug secures a second clinical win.
May 8, 2026 Angelini's $4B Catalyst Deal Expands CNS Portfolio Angelini acquires Catalyst for rare neuro drugs, enhancing U.S. market access.
May 7, 2026 Angelini's $4.1B Catalyst Buyout Expands Neurology Reach Aurinia beats earnings expectations; FDA reconsiders Ebvallo.
May 6, 2026 Bayer to acquire Perfuse Therapeutics for $300M Major M&A activity in biotech as Bayer expands its ophthalmology portfolio.
May 5, 2026 Cytokinetics' Myqorzo Success Fuels Growth Prospects Cytokinetics' drug Myqorzo meets efficacy goals in heart disease study, boosting sales outlook.
May 4, 2026 UCB's $2B Candid Deal Marks Shift in Autoimmune Strategy UCB's acquisition signals a major investment in T-cell engagers for autoimmune diseases.
May 1, 2026 Axsome expands Auvelity label; IPO surge continues Axsome's FDA win and recent IPOs signal evolving biotech landscape.
Apr 30, 2026 Chiesi's $1.9B KalVista acquisition signals robust M&A activity Chiesi's buyout of KalVista reflects strong interest in rare disease therapies.
Apr 29, 2026 GSK's reorg depends on upcoming Phase 3 results CEO Luke Miels hints at potential restructuring based on late-stage trial outcomes.
Apr 28, 2026 Eli Lilly's $2.25B gene therapy deal with Profluent Lilly's partnership aims to advance next-gen gene editing technologies.
Apr 27, 2026 Intellia's CRISPR therapy hits Phase 3 milestone Positive results could pave the way for FDA approval.
Apr 22, 2026 FDA Expands Tzield Use; Roche MS Drug Shows Promise Sanofi's Tzield approved for young children; Roche's MS drug data raises safety concerns.
Apr 21, 2026 Roche's MS Pill Shows Promise Amid Safety Concerns Roche's fenebrutinib delays MS relapses but raises liver toxicity issues.
Apr 20, 2026 Nektar's alopecia data fuels Phase 3 ambitions Nektar's promising mid-stage trial results may lead to a Phase 3 study.
Apr 18, 2026 UCB to Acquire Neurona for Up to $1.2B in Seizure Therapy UCB's acquisition diversifies its epilepsy treatment portfolio amid rising competition.
Apr 17, 2026 UCB Acquires Neurona for Up to $1.2B to Enhance Epilepsy Pipeline UCB's acquisition of Neurona marks a strategic move into cell therapy for epilepsy.
Apr 12, 2026 FDA Rejects Replimune's Melanoma Drug for Second Time Replimune faces regulatory challenges as FDA denies melanoma treatment again.